OrganaBio Expands to the San Francisco Bay Area with New PBMC Processing Laboratory in Hayward, California

Audio By Carbonatix

SAN FRANCISCO--(BUSINESS WIRE)--Dec 15, 2025--

OrganaBio, LLC, a leading provider of human research- and clinical-grade cellular starting materials and clinical trial support services today announced the opening of its newest cell processing and cryopreservation facility in Hayward, California, further strengthening its nationwide network supporting cell therapy developers and clinical trial sponsors.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251215548505/en/

OrganaBio opens up a new Peripheral Blood Mononuclear Cells (PBMC) processing lab in the Greater San Francisco area (Hayward, CA) to support rapid, time-sensitive isolation of PBMCs from clinical trial participant whole blood & leukopaks

The new Bay Area site located at 25801 Industrial Boulevard, Hayward, CA 94545 expands OrganaBio’s reach to one of the most vibrant biotech and life science hubs in the world. Strategically located near major academic institutions, clinical research centers, and biotechnology innovators, the Hayward site will enable faster, more efficient support for Northern California clinical sites requiring time-sensitive processing of clinical trial samples.

This expansion enables sponsors to have cryopreserved samples within 3-4 hours of sample collection - a critical factor for maintaining cell viability and function.

OrganaBio offers industry-leading turnaround times and exceptional quality metrics, with an average PBMC viability of 99.1% and PBMC recovery exceeding 2.9 e6/mL. OrganaBio’s exceptional performance is driven by a rigorously trained team, qualified across multiple internal and Sponsor-specific SOPs. These operators continuously refine their technique by routinely isolating PBMCs from leukopaks and whole blood in support of its cellular starting material products business.

OrganaBio’s operators also travel between facilities to ensure consistency, reproducibility, and quality across all sites, a critical factor as clinical programs scale and expand geographically.

“Our rapid turnaround time, averaging just 76 minutes from blood draw to the start of cell isolation, is not just an impressive metric; it is a critical differentiator for data integrity. The opening of our second West Coast lab in Hayward is a direct investment in maintaining this operational speed and quality, ensuring that our clinical partners receive the most viable and functionally relevant cellular products, regardless of where their trial sites are located.” - Sarah Alter, Ph.D., Laboratory Director, OrganaBio.

With bi-coastal operations, OrganaBio continues to build on its mission to accelerate access to high-quality donor materials and manufacturing solutions, supporting the rapid development and delivery of next-generation therapies.

About OrganaBio, LLC

OrganaBio provides ethically sourced starting materials and clinical trial support services for advanced therapies. With facilities on both coasts, the company offers primary cells, leukopaks, birth tissue derivatives, and sample processing services, delivering fast turnaround, high quality, and consistency for biopharma partners.

View source version on businesswire.com:https://www.businesswire.com/news/home/20251215548505/en/

CONTACT: Carlos Carballosa, PhD

VP of Sales

[email protected]

KEYWORD: CALIFORNIA UNITED STATES NORTH AMERICA

INDUSTRY KEYWORD: RESEARCH GENETICS CLINICAL TRIALS STEM CELLS OTHER HEALTH BIOTECHNOLOGY PHARMACEUTICAL HEALTH SCIENCE OTHER SCIENCE

SOURCE: OrganaBio, LLC

Copyright Business Wire 2025.

PUB: 12/15/2025 11:00 AM/DISC: 12/15/2025 11:00 AM

http://www.businesswire.com/news/home/20251215548505/en